Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy

  1. Rohit Loomba, MBBS, MHSc;
  2. Ayana Rowley, PharmD;
  3. Robert Wesley, PhD;
  4. T. Jake Liang, MD;
  5. Jay H. Hoofnagle, MD;
  6. Frank Pucino, PharmD; and
  7. Gyorgy Csako, MD
  1. From National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, Maryland.
    1. Figure 1.
      View larger version:
      Figure 1. Study flow diagram.
    2. Figure 2.
      View larger version:
      Figure 2. Forest plot of clinical trials assessing hepatitis B virus reactivation (top) and hepatitis B virus–related hepatic failure (bottom).

      *Preventive versus deferred lamivudine. †Preventive versus no lamivudine.

    3. Figure 3.
      View larger version:
      Figure 3. Forest plot of clinical trials assessing hepatitis B virus–related death (top) and hepatitis (bottom).

      *Preventive versus deferred lamivudine. †Preventive versus no lamivudine.

    Responses to this article

    • Hepatitis B reactivation due to cancer chemotherapy
      • Rohit Loomba and
      • Frank Pucino, PharmD and Gyorgy Csako, MD
      Ann Intern Med published online October 26, 2009
    • Prophylactic lamivudine for chemotherapy-induced hepatitis B reactivation
      • Chiun Hsu and
      • Ann-Lii Cheng and Pei-Jer Chen
      Ann Intern Med published online October 26, 2009
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med April 1, 2008 vol. 148 no. 7 519-528
    1. AbstractFREE
    2. » Figures
    3. Full Text
    4. Full Text (PDF)

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues